

## COURSE FACULTY, IAS–USA STAFF, BOARD OF DIRECTORS, AND VIRAL HEPATITIS ADVISORY BOARD FINANCIAL RELATIONSHIPS WITH COMMERCIAL ENTITIES

In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, course faculty, IAS–USA Board members, Viral Hepatitis Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the previous 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity. The **ACCME defines a commercial interest** as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The **ACCME** does not consider providers of clinical service directly to patients to be **commercial interests** – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.” Below are the financial interests that faculty members of this course have had within the past 12 months as of the date listed. View the [Faculty Financial Disclosure Policy](#).

### PORTLAND, MAINE—OCTOBER 25, 2018

Workshop Hosts	
<b>Kinna Thakrar, DO, MPH</b> Assistant Professor of Medicine Maine Medical Center/Tufts University School of Medicine InterMed Infectious Disease Portland, Maine	<i>Dr Thakrar has no relevant financial affiliations to disclose. (Updated 06/17/18)</i>
Workshop Leaders	
<b>Arthur Y. Kim, MD</b> Associate Professor of Medicine Harvard Medical School Director, Viral Hepatitis Clinic Division of Infectious Diseases Massachusetts General Hospital Boston, Massachusetts	<i>Dr Kim has no relevant financial affiliations to disclose. (Updated 10/19/18)</i>
<b>Kristen M. Marks, MD</b> Assistant Professor of Medicine Division of Infectious Diseases Weill Cornell Medical College New York, New York	<i>Dr Marks was awarded research grants paid to her institution from Bristol-Myers Squibb, Merck, and Gilead Sciences, Inc. (Updated 10/12/18)</i>
<b>Kenneth E. Sherman, MD, PhD</b> Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio	<i>Dr Sherman has received research grants or contracts awarded to his institution from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Inc, Inovio Pharmaceuticals, Intercept Pharmaceuticals, Inc, MedImmune, and Merck. He has served as an advisory board member or a consultant to Abbott Laboratories, Inovio, Merck, and MedImmune. He has also served on data safety monitoring boards for Watermark and Medpace. (Updated 10/19/18)</i>
IAS–USA CME Staff	
<b>Donna M. Jacobsen</b> Executive Director	<i>Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 10/19/18)</i>
IAS–USA Board of Directors	
The nonstaff members of the IAS–USA Board of Directors are not compensated for their roles in governing and overseeing the IAS–USA. Please see <a href="https://iasusa.org/about/ias-usa-board-of-directors/">https://iasusa.org/about/ias-usa-board-of-directors/</a> for information about board members and a link to up-to-date financial disclosure information.	
IAS–USA Viral Advisory Board	
The members of the IAS–USA Viral Hepatitis Advisory Board are not compensated for their roles in governing and overseeing the IAS–USA viral hepatitis educational efforts. Please see <a href="https://iasusa.org/activities/live-courses/hepatitis-c-virus-courses/viral-hepatitis-advisory-board/">https://iasusa.org/activities/live-courses/hepatitis-c-virus-courses/viral-hepatitis-advisory-board/</a> for information about the financial disclosures for the IAS–USA Viral Hepatitis Advisory Board.	